New stock news | Danuo Pharmaceuticals has passed the hearing of the Hong Kong Stock Exchange, owning core products such as Lifortinib (TNP-2198) and Lifujinone (TNP-2092)

According to the disclosure by the Hong Kong Stock Exchange on May 6, Suzhou Dianuo Medicine Co., Ltd. (referred to as "Dianuo Medicine") is undergoing a listing hearing on the Main Board of the Hong Kong Stock Exchange, with CITIC SEC and Bank of China International as joint sponsors for the IPO. Dianuo Medicine focuses on the discovery, development, and commercialization of differentiated innovative drug products to address unmet clinical needs in the areas of bacterial infections and bacterial metabolism-related diseases. The company has established a pipeline consisting of seven innovative projects, including two core products: Lefenoconazole (TNP-2198), a new molecular entity ("NME") candidate drug, used as part of triple therapy in combination with amoxicillin and proton pump inhibitors (PPIs) for the treatment of Helicobacter pylori ("H. pylori") infection, as well as for the treatment of bacterial vaginosis and difficult clostridium difficile infection as a monotherapy; and Lefquine (TNP-2092 injection), a three-target candidate drug for the treatment of implant-related bacterial infections (such as prosthetic joint infections (PJIs), left ventricular assist device infections (LVADIs), and central venous catheter-related bloodstream infections (CRBSIs)). Dianuo Medicine is implementing a commercialization strategy aimed at maximizing the value of its candidate drugs. For the upcoming commercialization of Lefenoconazole in China, the company plans to adopt a promotion strategy combining partners and its own commercialization team. The company has signed an exclusive commercial cooperation agreement with Grand Life Sciences for the commercialization of Lefenoconazole in Greater China (excluding Taiwan), to fully leverage their sales and marketing expertise as well as their extensive network and resources. Dianuo Medicine continues to invest resources in research and development to lay the foundation for long-term development. Research and development expenses attributable to the company's core products in 2023, 2024, and 2025 are RMB 99.70 million, RMB 64.20 million, and RMB 60.50 million, respectively, accounting for 91.9%, 91.9%, and 84.1% of the total research and development expenses. The company's research and development team consists of 39 members, with over 50% of them holding master's or doctoral degrees in relevant fields.